Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

PP405 now has a Wikipedia page, generating more discussion and attention. One user plans to continue using finasteride until PP405 is proven effective and widely available.

The conversation discusses hair loss treatments, including minoxidil, finasteride, biotin, folic acid, zinc, micro-needling, niacin, and cipaxil, with the user preparing for a hair transplant. The user experiences side effects with topical finasteride and is hesitant to try oral dutasteride.

The conversation discusses hair regrowth after 5 months of using finasteride and minoxidil, along with 3 sessions of laser therapy and exosomes. The user is hopeful about regaining their bangs.

Users discussed experiences with Everychem's solution similar to PP405 for hair loss, noting some positive results like increased hair thickness and new growth. There was skepticism about the product's legitimacy and safety, with some users reporting early signs of effectiveness and others expressing concerns about the lack of evidence and safety profiles.

Natural vitamins like pumpkin seed oil, saw palmetto, and ecklonia cava are discussed for their potential to lower DHT levels. They may work similarly to finasteride but are significantly weaker.

A 22-year-old male has been using finasteride for 5.5 months to address hair loss, experiencing diffuse density loss but no hair fall. He corrected a vitamin D deficiency and noticed new hair growth, seeking advice on whether thinning stabilizes after 3-6 months or if switching to dutasteride is advisable.

The user experienced significant hair growth after 5 months using topical and oral minoxidil and finasteride, along with tretinoin, and correcting vitamin D, B12, and thyroid levels. They are currently experiencing a second shedding phase but are pleased with the overall progress.

The user has been using finasteride and minoxidil for five years but continues to experience hair thinning and density loss. They are considering switching to dutasteride for potentially better results.

The user experienced hair regrowth after 5 months on 5 mg oral minoxidil and 1 mg dutasteride, following a year of ineffective finasteride use. They noticed progress after an initial shedding phase and hope for further improvement, with expectations of near-max regrowth around 18 months.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The user experienced another hair shed and plateau at month 5 using 6% minoxidil and 0.3% finasteride, with an itchy scalp indicating potential regrowth. They find the topical spray easy to use and saw results within two months, but caution that stopping use may lead to hair loss.

A 20-year-old is experiencing ongoing hair shedding despite using 5mg minoxidil and 1mg finasteride for five months. They are advised to be patient, as shedding can be part of the treatment process, and to consult a dermatologist for further guidance.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

The user switched from finasteride to dutasteride due to side effects and hair thinning, and experienced thicker hair with no side effects after five months. The conversation includes positive feedback and questions about the transition process.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

The user shared their 5-month progress using Minoxidil, finasteride, and weekly dermastamping, noting improvements in their hairline and crown. They also use a saw palmetto shampoo and have not experienced shedding yet.

The user is experiencing hair thinning and is using minoxidil, dutasteride injections, and red light therapy with little success after 4.5 months. Suggestions include switching to finasteride instead of dutasteride injections.

The user experienced significant hair growth using topical finasteride and minoxidil but noticed nipple changes, suggesting early gynecomastia. They plan to stop the treatment and consider blood work to check hormonal balance.

The conversation is about a user's 5-month progress using topical Minoxidil (5%) and Finasteride (0.1%) twice daily, along with derma stamping, improved Vitamin D levels, and increased protein intake for hair regrowth. The user is considering dutasteride if progress plateaus and uses a sulfate and paraben-free shampoo.

JXL069, also known as PP405, did not lead to hair regrowth after a year of testing. The lack of results may be due to formulation issues, leading to a final attempt with an improved vehicle.

The user has been using topical finasteride and oral minoxidil for hair loss but has seen no results after 5.5 months and 1 year, respectively. Many commenters suggest the user's hair looks good, recommend continuing treatment for maintenance, and discuss potential side effects and alternative treatments.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The user has been using a treatment of 0.1% topical finasteride, 5% minoxidil, dermastamping, and vitamin D3 supplements for 85 days and is seeing good progress. Other users note the effectiveness of topical finasteride despite it being less potent.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.